Erlotinib, another selective EGFR-TKI, increase the ROS levels in lung cancer cells, promoting JNK phosphorylation that activates c-Jun and caspase-3 to lead to apoptosis [15]. This evidence concerns the gene CASP3 and lung carcinoma.